TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ABVX

Abivax S.A.

Healthcare · Biotechnology

107.00$ +4.7% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Abivax S.A. (ABVX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.6% of the shares are freely tradable; institutional investors hold 70.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 70.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 79.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 8.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 87Mio.

Largest Shareholders

Institutions

Institutions ABVX
Name Stake (%) Shares Change (%) Date
TCG Crossover Management, LLC 6.89 6,007,834 -7.3 06/30/2026
UBS Group AG 5.21 4,547,406 +2.8 03/31/2026
Darwin Global Management, Ltd. 4.15 3,621,583 +4.4 06/30/2026
Helikon Investments Ltd 3.19 2,787,131 +175.0 06/30/2026
Morgan Stanley - Brokerage Accounts 1.95 1,704,958 -45.9 03/31/2026
Caligan Partners LP 1.79 1,557,924 +6.6 06/30/2026
Vestal Point Capital LP 1.72 1,500,000 -21.1 03/31/2026
Citadel Advisors Llc 1.65 1,438,352 +164.2 06/30/2026
ADAR1 Capital Management LLC 1.60 1,394,019 +5.8 03/31/2026
Westfield Capital Management Company, L.P. 1.50 1,309,825 -1.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?